

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) An oral drug delivery system which comprises a biliquid foam comprising:

from 1 to 20% by weight of a continuous hydrophilic phase,

from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase,

the [[said]] pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight,

said poorly water-soluble drug dissolving in water in an amount of less than 1% by weight, and

the biliquid foam including therein from 0.5 to 5% by weight of a surfactant to enable the formation of a stable biliquid foam,

all percentages being based upon the total weight of the formulation,

wherein the pharmaceutically acceptable oil comprises a mono-, di-, or triglyceride, or a mixture thereof comprising C_6-C_{40} fatty acid chains.

2. (Previously Presented) The oral drug delivery system as claimed in claim 1, wherein the continuous hydrophilic phase is an aqueous phase.

3. (Previously Presented) The oral drug delivery system as claimed in claim 2, wherein the aqueous phase is water.

4. (Previously Presented) The oral drug delivery system as claimed in claim 2, wherein the aqueous phase incorporates a salt or a co-solvent therein.

5. (Previously Presented) The oral drug delivery system as claimed in claim 1, wherein the continuous hydrophilic phase is a non-aqueous solvent.

6. (Previously Presented) The oral drug delivery system as claimed in claim 5, wherein the non-aqueous solvent is an aliphatic alcohol, polyethylene glycol, propylene glycol or glycerol, or mixtures thereof.

7. (Canceled)

8. (Previously Presented) The oral drug delivery system as claimed in claim 7, wherein the mono-, di- or triglycerides are the glycerol esters of fatty acids containing from 6 to 22 carbon atoms.

9. (Previously Presented) The oral drug delivery system as claimed in claim 1, wherein the surfactant comprises an alkyl polyglycol ether, an alkyl polyglycol ester, an ethoxylated alcohol, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene fatty acid ester, a polyoxyethylene fatty acid ester, an ionic or non-ionic surfactant, a hydrogenated castor oil/polyoxyethylene glycol adduct containing from 25 to 60 ethoxy groups, a castor oil/polyoxyethylene glycol adduct containing from 25 to 45

ethoxy groups, or mixtures thereof.

10. (Previously Presented) The oral drug delivery system as claimed in claim 1, which includes therein a co-emulsifier in an amount sufficient to complete the solubilization of the poorly water-soluble drug.

11. (Previously Presented) The oral drug delivery system as claimed in claim 10, wherein the co-emulsifier is a phosphoglyceride or a phospholipid.

12. (Previously Presented) The oral drug delivery system as claimed in claim 1, wherein the discontinuous phase comprises from 85 to 96% by weight of the biliqid foam.

13. (Previously Presented) The oral drug delivery system as claimed in claim 12, wherein the discontinuous phase comprises from 90 to 95% by weight of the biliqid foam.

14. (Previously Presented) The oral drug delivery system as claimed in claim 1, wherein the continuous hydrophilic phase comprises from 2 to 10% by weight of the biliqid foam.

15. (Canceled)

16. (Previously Presented) The oral drug delivery system as claimed in claim 1, wherein the poorly water-soluble drug is an analgesic or anti-inflammatory agent, an anthelmintic, an anti-arrhythmic agent, an anticoagulant, an anti-depressant, an anti-diabetic, an anti-epileptic, an antifungal agent, an anti-gout agent, an anti-hypertension agent, an antimalarial, an anti-migraine agent, an anti-muscarinic agent, an antineoplastic agent, an anti-protozoal agent, an anti-thyroid agent, an anxiolytic, a sedative, hypnotic or neuroleptic agent, a corticosteroid, a diuretic, an anti-Parkinsonian agent, a gastro-intestinal agent, a histamine H-receptor antagonist, a lipid regulating agent, an anti-anginal agent, a nutritional agent, an opioid analgesic, a sex hormone, a stimulant, or a therapeutic mixture thereof.

17. (Previously Presented) The oral drug delivery system as claimed in claim 1, which is in a unit dosage form.

18. (Previously Presented) The oral drug delivery system as claimed in claim 17, wherein the unit dosage form comprises capsules filled with the biliquid foam.

19. (Previously Presented) The oral drug delivery system as claimed in claim 18, wherein the capsules are hard or soft gelatin capsules.

20. (Previously Presented) The oral drug delivery system as claimed in claim 1, which is in the form of a dilutable concentrate.

21. (Previously Presented) The oral drug delivery system as claimed in claim 20, which is infinitely dilutable in a co-solvent.

22. (Previously Presented) The oral drug delivery system as claimed in claim 1, for use in a method of treatment by oral administration to the human or animal body.

23. (New) An oral drug delivery system which comprises a biliqid foam comprising:

from 1 to 20% by weight of a continuous hydrophilic phase,

from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase,

wherein the pharmaceutically acceptable oil is not peanut oil,

wherein the pharmaceutically acceptable oil comprises a mono-, di-, or triglyceride, or a mixture thereof,

the pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight,

said poorly water-soluble drug dissolving in water in an amount of less than 1% by weight, and

the biliqid foam including therein from 0.5 to 5% by weight of a surfactant to enable the formation of a stable biliqid foam,

all percentages being based upon the total weight of the formulation,